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SUMMARY
A new purification method for tumor-specific antigens is described. The TS-l antigen was
purified with ammonium sulfate and fractionation by column chromatography, Sephadex G 50,
G 200 and Can A Sepharose 4B. It was shown using the double immunodiffusion test that the
TS-l and CEA had a common antigenic determinant.
The TS-2 antigen, which was purified by a simpler method using proteolysis of Pronase E
and fractionation by column chromatography, was also a tumor-specific antigen. Anti-TS-l
serum had crossreactivity with TS-2 antigen, but anti-CEA and anti-NCA had no crossreactivity
in double gel diffusion with TS-2 antigen.
It was shown using the immunofluorescence test and enzyme-labelled antibody technique
that TS-1 and TS-2 antigens localized only on the cancer cell surface. They were not localized
on the normal tissue of bronchial epithelium, mucous glands, vascular tissue or alveoli. The
sedimentation coefficients of TS-1 and TS-2 antigens, which were measured by boundary ultra-
centrifugation, were 6.81 and 1. 65, respectively. Sugar parts of the TS-1 antigen were com-
posed of fucose, galactose, glucose, N -acetylglucosamine and sialic acid, while those of the TS-2
antigen were composed of fucose, galactose, N-acetylgalactosamine and unknown sugars. The
protein parts of the TS-l and TS-2 antigens accounted for 11. 3% and 15. 1%, respectively.
While TS-1 antigen and CEA showed affinity to Can A, TS-2 antigen did not. These results
suggested that TS-l and TS-2 antigens were cancer specific and that TS-l antigen was divided
by the proteolysis with Pronase E into TS-2 antigen and NCA.
INTRODUCTION
Recent years have seen an increasing number of reports on the presence of tumor-associated
antigens in human lung cancers and methods for their purificationl - 6). The TS antigen, which
was found by Ikeda et aI, is one such tumor-associated antigen7 - S). It is a mucoprotein and is
extracted from lung cancer specimens using the method of Winzler for isolation of mucoprotein
from serum with ammonium sulfate9), and is purified by column chromatography. It was also
- 43-
and enzyme-labelled antibody technique that TS
It was also verified that the TS antigen has a
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confirmed using the immunofluorescence test
antigen is localized on tumor cell surface10).
similar antigenic determinant to CEA.
Here, we report details of the purification methods and the characteristics of TS antigens:
TS-1 antigen, which is a more highly purified TS antigen, and TS-2 antigen, which is purified
by a simpler, easier way.
MATERIALS AND METHODS
1. Purification of Tumor-specific-1 antigen (TS-1 antigen)
Preparatz'on of crude TS-1 antigen by ammonium sulfate
Solid tumors, which contained different histological types of lung cancer, were obtained at
surgery and immediately frozen at - 20°C until use. These tumor materials were thawed and
homogenized with 2 volume of distilled water. The homogenate was centrifuged for 30 minutes
at 4°C and 10000 Xg. The pellet was then discarded. The supernatant was collected as tumor
extract.
Further preparation of the antigen was performed using the method of Winzler for isolation
of mucoprotein from serum with ammonium sulfate9>.
The supernatant, to which was added one-tenth volume of 1 M sodium acetate, was adjusted
with ammonium sulfate to final concentration of 2.73 M. The mixture was again centrifuged,
and the pellet was discarded. The pH of the supernatant was brought to 4. 9 with 1 N hydro-
chloride solution. The mixture was again centrifuged and the supernatant was collected. The
pH of the supernatant was further acidified to 3. 6 with a 1 N hydrochloride solution. The
mixture was centrifuged. The supernatant was satured with ammonium sulfate and hIed at 4°C for
48 hours. Then, the supernatant was centrifuged and the pellet was dialyzed and lyophilized.
This was named crude TS-1 antigen (TS-l antigen).
Puricatz'on of TS-l antigen
The crude TS-l antigen was purified by fractionation with column chromatography. At
first, the solution of crude TS-l antigen was separated on a column of CM Sephadex (G50) and
the column was washed out with O. 1 M acetate buffer (pH 4. 0) containing O. 5 M N ad. The
eluted first fraction was dialyzed and lyophilized. Then, this fraction was again separated on
Sephadex G-200 and the first fraction, which was eluted in saline, was dialyzed and lyophilized.
This first fraction was applied to a column of Con A Sepharose 4B and the column was washed
out with O. 02 M phosphated buffer (pH 7. 0) containing 1M N ad. The column was incubated
for 12 hours with 1 M alpha-methyl-D-glucoside in phosphate buffer and washed out with the
same buffer solution. Finally, this Con A linked fraction was separated on a column of Sepharose
4B. The eluted first fraction is the purified TS-1 antigen (Figure 1).
Production of antiseru m
Antiserum to TS-1 antigen was produced in rabbit. One mg of TS-1 antigen, which was
emulsified in complete Freund adjuvant, was injected subcutaneously into the back of rabbit. Six
weeks later, the rabbit serum was obtained and the gamma-globulin fraction was prepared with
semi saturated ammonium sulfate. This 5% saline solution of anti-TS serum was absorbed




Column 1.6x40cm (Con A-Sepharose 48)
pH 7.0, 0.02 M PB (add l M NaCI)
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Fig. 1 Con A-Sepharose 4B chromatography of 1'S-1 antigen preparation
with a 10% saline solution of lyophilized normal lung extract with an incubation time of 1 hour
at 37°C and then, for 12 hours at 4°C. The anti-TS-1 serum was also absorbed with pooled
human serum of A, B groups under identical conditions. The mixture was centrifuged and the
supernatant was used as the anti-TS-1 serum.
11. Purification of Tumor-specific-2 antigen (TS-2 antigen)
Purification of T 5-2 antigen by proteolysis wlth Pronase E
The tumor materials, which were collected at the same time as those which underwent
purification for TS-1 antigen, were thawed and homogenized with 2 volumes of distilled water.
Then, the tumor homogenate was mixed with 1 N solution of sodium hydroxide to a final
concentration of O. 1 normal and dissolved with 1% sodium azide to a final concentration of
0.2%. The homogenate was incubated for 48 hours at 4°C. The pH of this homogenate was
adjusted to 7. 5 with 1 N solution of hydrochloride and O. 1 M tris-hydrochloride buffer (pH 8. 0).
Then, the homogenate was exposed to the Pronase E at the rate of 3 mg per gram of tumor wet
weight.
This homogenate was incubated for 12 hours at 3rC and dissolved. After incubation, the
pH of the homogenate was brought to 7.5 with the O. 1 M tris-hydrochloride buffer (pH 8. 0)
and Pronase E was again added as before. Incubation was performed for 12 hours at 37°C.
The homogenate was digested and filtrated. The filtrate was saturated with ammonium sulfate
and centrifuged. The pellet was dialyzed. After adding ethanol in a final concentration of 50%,
it was again centrifuged. The pellet was dialyzed and lyophilized. The 5% solution of this
extract was applied to a column of Sephadex G-50 and washed with saline. The first fraction
was then separated on a column of Sephadex G-200 and the first fraction considered 1'S-2
antigen.
The TS-2 antigen was also purified from gastric cancer using the same method.
Production ~f antiserum
The antiserum to TS-2 antigen was produced by the same method as for the anti-TS-1 serum.
Absorption with normal lung extracts and pooled human serum of A, B groups were also
performed.
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III. Specificity and antigenicity of the TS-l and TS-2 antigens
Anti-TS-l serum was tested for titer and specificity against TS-l antigen and extracts of
normal lung, liver, kidney and fetal liver tissues by the gel diffusion precipitation reaction.
Anti-TS-2 serum was also tested for titer and specificity against anti-CEA and anti-NCA by
the same method. The TS-2 antigen from gastric cancer was also tested for antigenicity and
specificity.
IV. Localization of TS-l and TS-2 antigens
The localization of TS-l and TS-2 antigens were histologically determined by the immuno-
fluorescence test and enzyme-labelled antibody technique. The details of the method used have
been described by Matsubara10l •
V. Analysis of the TS-l and TS-2 antigens
The TS-l and TS-2 antigens were treated with 2-mercaptoethanol and electrophoresis was
performed in acrylamide gels with SDS in phosphate buffer. The sedimentation value of the
antigens were also measured by the Beckmann Spinco Model.
The carbohydrate and amino acids composition of the TS-l and TS-2 antigens were analyzed.
RESULTS
There was no reactivity between anti-TS-l serum and extracts of normal lung, liver, kidney or
fetal liver. Anti-TS-l, anti-CEA and anti- NCA sera showed precipitation line patterns identical
with TS-l antigen, indicating the existence of a common antigenic determinant among them. The
precipitation line between anti-TS-l serum and TS-l antigen was distinct (Figure 2). Figure 3








Fig. 2 Double immunodiffusion test of TS-l antigen against anti-NCA, anti-CEA and anti-TS-l
serum.
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Fig. 3 Double immunodiffusion test of TS-2 antigen against anti-NCA, anti-CEA and anti-TS-2
serum.
against anti-CEA and anti-NCA sera. Neither TS-2 antigen from lung cancer nor TS-2 antigen from
gastric cancer reacted with anti-CEA sera. A precipitation line was observed only between anti-TS-2
serum and both TS-2 antigens. The precipitation lines of both TS-2 antigens fused (Figure 3).
Specific fluorescence by the indirect immunofluorescent staining of lung cancer with anti-TS-l
serum was observed on cancer cell surfaces of all histological types of lung cancer. It was
especially prominent in adenocarcinoma (Figure 4). However, there was no specific fluorescence
in normal tissues of bronchial epithelium, mucous glands, vascular tissue or alveoli. By immuno-
peroxidase staining, only the cancer cell surfaces were stained (Figure 5). Further, by immuno-
electron microscopy and staining with peroxidase-labelled anti-TS-l serum, it was shown that
the antigen-antibody complex was localized on the cancer cell surfaces (figure 6).
The specific fluorescence of lung cancer with anti-TS-2 serum as well as that of anti-TS-l
serum was observed on cancer cell surfaces of different histological types of lung cancer
(Figures 4, 5, 6). There was no specific fluorescence with anti-TS-2 serum in normal tissues of
bronchial epithelium, mucous glands, vascular tissue or alveoli. In gastric cancer, specific
Table 1. Carbohydrate composition
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Fig. 5 Immunoperoxidase staining of adenocarcinoma of the lung.
A: Anti-TS-l serum (X400)








































Fig.6 Immuno-electron microscopy staining with peroxidase-labelled anti-TS-l serum (A) and anti-
TS-2 serum (B). The antigen-antibody complexes are localized only on the cancer cell

























































































Fig. 7 Ultracentrifugal analysis of TS-l and TS-2 antigens. A single peak is levealed in both
cases. A: TS-l antigen B: TS-2 antigen enf-'
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Table 2. Amino acid composition of TS-1 and TS-2 antigen




Asparatic acid 0.67 1.67
Threonine 2.01 1. 48
Serine 1. 35 1. 26
Glutamic acid 0.81 0.91
Proline 1. 05 0.55
Glycine 0.38 1. 77
Alanine 0.54 0.78
Cysteine 0.22 (1/2 Cyst.)
Valine 0.94 0.65
Methionine 0.59 0.01
Isoleucine 0.54 1. 93





Total 11. 35 15.09
% TS (TS-l, TS-2), percentage of individual amino acid as a portion of the total
weight of TS analyzed.
fluorescence was also observed on cancer cell surfaces.
The electrophoretic mobilities of TS-l and TS-2 antigen on SDS acrylamide gel migrated
near to the gamma- globulin region.
By ultracentrifugal analysis, TS-l and TS-2 antigens each revealed the presence of a single
peak. The sedimentation constants of TS-l and TS-2 antigens were 6. 81 Sand 1. 65 S, res-
pectively (Figure 7).
Carbohydrate and ammo acid compositions are summarized III Tables 1 and 2.
DISCUSSION
The TS antigen, which was purified by Ikeda et aP-8), is a tumor-specific antigen found on
tumor cell surfaces of lung cancer10). It was confirmed that the TS antigen had an antigenic
determinant in common with CEA by the gel diffusion precipitation reaction.
In our studies of TS antigen, in order to determine its antigenic properties, we treated the
TS antigen with periodate to degrade the sugars in glycoproteins and with Pronase E, a
proteolytic enzyme, for the proteolysis of glycoproteins. In gel diffusion, the antigenicity of TS
antigen against anti-TS serum was lost by the degradation of sugars, but was not lost by the
proteolysis of proteins (Figure 8). This finding can be explained by assuming that the antigenic
determination of the TS antigen was based on the sugars in glycoproteins. Thus, the TS
antigen that was purified with ammonium sulfate and fractionated by column chromatography
was named TS-l antigen. Proteolysis of Pronase E was applied to the purification of tumor
specific-antigen and we developed a simpler method for the purification of TS antigen. This was






Fig. 8 Double immunodiffusion test of TS-antigens treated with periodate and Pronase E.
dubbed the TS-2 antigen.
The main difference between TS-l, TS-2 and CEA is that of molecular size, as determined
by analytical ultra-centrifugation data. The sedimentation coefficients of the TS-1 and TS-2
antigens were 6.81 and 1. 65, respectively, while that of CEA ranged from 6. 9 to 8. OlD.
CEA contained a moderate amount of mannose and N-acetyl-galactosaminell-12), while TS-2
antigen, which was absorbed with pooled blood A and B groups, had more N-acetyl-galactosamine
and little mannose.
The protein parts of the TS-1 and TS-2 antigens account for 11. 3% and 15. 1%, respectively,
and are much smaller than that of CEA, which was reported to range from 16.2% to 43.3%13).
TS-l and CEA have an affinity to Can A14l. However, TS-2 antigen did not show any affinity
to Con A. NCA showed cross-reactivity to TS-1 and CEA15-16), but not to TS-2 antigen.
TS-1 and TS-2 antigens localized only on the cancer cell surfaces. They were not present
on the normal cells of the lung.
In our study, TS-1 antigen was divided by proteolysis with Pronase E into TS-2 antigen
and NCA. TS-2 antigen has a smaller amount of protein than CEA and TS-1 antigen, and
contains no NCA. Although the purification method for TS-1 antigen is different from that of
CEA, it shares a common antigenicity with CEA; however, the antigenicity of TS-2 is different
from that of CEA. TS-2 antigen purified from gastric cancer by the same method has common
antigenic characteristics.
In 1979, the WHO collaborative study on lung tumor-associated antigens was held at Charing
Cross Hospital. Eleven groups of workers were recruited. to compare lung tumor-associated
antigens extracted from tumor materials of various histological types by means of various extraction
and purification methods17). TS-2 antigen showed crossreactivity only to antiserum of Veltri. The
TS-2 antigen is different from other tumor-associated antigens except for one tumor-associated
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antigen extracted by Veltri from cell membranes with Triton and separated on DEAE-cellulose18).
Whether the TS-2 antigen is identical with that of Veltri or not remains to be determined.
However, it is confirmed that TS-2 antigne is a tumor-associated antigen.
The clinical application of TS-2 antigen for the diagnosis of lung cancer has already been
done.
The tumor-specific antibodies in the regional non-metastatic lymph nodes of patients with
lung cancer were studied by immunofluorescent staining method. Cells with TS-2 antibody were
demonstrated in 20 of 35 cases. No correlation could be established between the presence of the
TS-2 antibody in the lymph nodes and stage of tumor. However, these findings are very
interesting with regard to the extirpation of regional lymph nodes in the surgical treatment of
lung cancer19).
The cutaneous delaved hypersensitivity reaction was performed with TS-2 antigen m 288
patients with lung cancer to evaluate their immunocompetence levels, and it was confirmed that
the response to TS-2 antigen was reduced in inverse proportion to stage advancement20).
Further, studies concerning the measurement of TS-2 antigen in the serum of lung cancer
patients by radioimmunoassay methods are still under way.
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